These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27260788)

  • 1. [Place of azathioprine in the treatment of giant cell arteritis].
    Boureau AS; de Faucal P; Espitia O; De Decker L; Agard C
    Rev Med Interne; 2016 Nov; 37(11):723-729. PubMed ID: 27260788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.
    de Boysson H; Boutemy J; Creveuil C; Ollivier Y; Letellier P; Pagnoux C; Bienvenu B
    Semin Arthritis Rheum; 2013 Aug; 43(1):105-12. PubMed ID: 23453684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients].
    Broner J; Arnaud E
    Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving therapeutic options for patients with giant cell arteritis.
    Pipitone N; Salvarani C
    Curr Opin Rheumatol; 2008 Jan; 20(1):17-22. PubMed ID: 18281852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
    Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
    Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical, laboratory, radiological features, and outcome in 26 patients with aortic involvement amongst a case series of 63 patients with giant cell arteritis].
    Daumas A; Rossi P; Bernard-Guervilly F; Francès Y; Berbis J; Durand JM; Kaplanski G; Ebbo M; Harlé JR; Weiller PJ; Serratrice J; Disdier P; Gayet S; Villani P; Granel B
    Rev Med Interne; 2014 Jan; 35(1):4-15. PubMed ID: 23906779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
    Proven A; Gabriel SE; Orces C; O'Fallon WM; Hunder GG
    Arthritis Rheum; 2003 Oct; 49(5):703-8. PubMed ID: 14558057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of oral cyclophosphamide in the treatment of giant cell arteritis.
    Quartuccio L; Maset M; De Maglio G; Pontarini E; Fabris M; Mansutti E; Mariuzzi L; Pizzolitto S; Beltrami CA; De Vita S
    Rheumatology (Oxford); 2012 Sep; 51(9):1677-86. PubMed ID: 22627726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres.
    Loock J; Henes J; Kötter I; Witte T; Lamprecht P; Schirmer M; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S70-6. PubMed ID: 22640650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of giant-cell arteritis, a literature review.
    Watelet B; Samson M; de Boysson H; Bienvenu B
    Mod Rheumatol; 2017 Sep; 27(5):747-754. PubMed ID: 27919193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review].
    Kieffer P; Hinschberger O; Ciobanu E; Jaeger-Bizet F; Drabo A; Mostoufizadeh T; Martzolff L
    Rev Med Interne; 2014 Jan; 35(1):56-9. PubMed ID: 24075627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose].
    Chevalet P; Barrier JH; Glémarec J; el Kouri D; Hamidou M; de Wazières B; Duhamel E; Jégo P; Maugars Y; Planchon B; Rodat O
    Rev Med Interne; 2001 Jul; 22(7):624-30. PubMed ID: 11508155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
    Alba MA; García-Martínez A; Prieto-González S; Espígol-Frigolé G; Butjosa M; Tavera-Bahillo I; Rodríguez-Pintó I; Hernández-Rodríguez J; Cid MC
    Semin Arthritis Rheum; 2014 Jun; 43(6):772-7. PubMed ID: 24315461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients.
    Ly KH; Dalmay F; Gondran G; Palat S; Bezanahary H; Cypierre A; Fauchais AL; Liozon E
    Medicine (Baltimore); 2016 Oct; 95(42):e4974. PubMed ID: 27759628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients.
    Chevalet P; Barrier JH; Pottier P; Magadur-Joly G; Pottier MA; Hamidou M; Planchon B; El Kouri D; Connan L; Dupond JL; De Wazieres B; Dien G; Duhamel E; Grosbois B; Jego P; Le Strat A; Capdeville J; Letellier P; Agron L
    J Rheumatol; 2000 Jun; 27(6):1484-91. PubMed ID: 10852275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunosuppressive agents in Horton's disease. Which drug for which indication?].
    Roblot P
    Ann Med Interne (Paris); 1998 Nov; 149(7):441-7. PubMed ID: 9921398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.